直肠癌前切除术后围术期并发症:新辅助方案是否影响?
该单中心回顾性队列研究纳入2010至2018年415例非转移性直肠癌行全直肠系膜切除术患者,比较短程放疗后延时手术(SC-TNT)与常规放化疗(CRT)的围术期并发症。结果显示两组严重围术期并发症(9.6% vs 12.0%,P=0.46)和总体并发症(39.7% vs 37.5%,P=0.64)无显著差异,多因素分析中新辅助方案与严重并发症无关(OR 0.42,95%CI 0.04-4.70,P=0.48)。
要点
- SC-TNT与CRT相比未显著增加严重围术期并发症风险。
- 两组总体并发症、术中并发症及切缘等次要结局均无显著差异。
- 高位置肿瘤和淋巴结阳性患者更倾向于接受SC-TNT。
核心结论
- 在直肠癌SC-TNT后行前切除术的患者中,围术期并发症与CRT相比无显著关联。
- SC-TNT相比CRT并未显著增加围术期并发症风险。
研究设计与样本
- 单中心回顾性队列研究,纳入2010至2018年415例非转移性直肠癌行全直肠系膜切除术患者。
- 156例(38%)接受SC-TNT,259例(62%)接受CRT。
- 采用单因素分析和严重围术期并发症的logistic回归。
主要发现
- 严重围术期并发症发生率SC-TNT组9.6%,CRT组12.0%,P=0.46。
- 总体围术期并发症发生率SC-TNT组39.7%,CRT组37.5%,P=0.64。
- 多因素分析中新辅助方案与严重围术期并发症无显著关联(OR 0.42,95%CI 0.04-4.70,P=0.48)。
- 新辅助方案与任何次要结局均无显著关联。
- 高位置肿瘤(69.9% vs 47.5%,P<0.0001)和淋巴结阳性(76.9% vs 62.6%,P=0.004)患者更可能接受SC-TNT。
临床怎么用
- 对于适合SC-TNT的直肠癌患者,不应因担心围术期并发症而避免该方案。
- SC-TNT可作为CRT的替代选择,不显著增加围术期并发症风险。
局限性
- 单中心回顾性设计。
- 样本量415例,事件数有限。
- 两组基线特征存在差异(肿瘤位置和淋巴结状态)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigate the association between neoadjuvant treatment strategy and perioperative complications in patients undergoing proctectomy for nonmetastatic rectal cancer. SUMMARY OF BACKGROUND DATA: Neoadjuvant SC-TNT is an alternative to neoadjuvant CRT for rectal cancer. Some have argued that short-course radiation and extended radiation-to-surgery intervals increase operative difficulty and complication risk. However, the association between SC-TNT and surgical complications has not been previously investigated. METHODS: This single-center retrospective cohort study included patients undergoing total mesorectal excision for nonmetastatic rectal cancer after SC-TNT or CRT between 2010 and 2018. Univariate analysis of severe POM and multiple secondary outcomes, including overall POM, intraoperative complications, and resection margins, was performed. Logistic regression of severe POM was also performed. RESULTS: Of 415 included patients, 156 (38%) received SC-TNT and 259 (62%) received CRT. The cohorts were largely similar, though patients with higher tumors (69.9% vs 47.5%, P < 0.0001) or node-positive disease (76.9% vs 62.6%, P = 0.004) were more likely to receive SC-TNT. We found no difference in incidence of severe POM (9.6% SC-TNT vs 12.0% CRT, P = 0.46) or overall POM (39.7% SC-TNT vs 37.5% CRT, P = 0.64) between cohorts. Neoadjuvant regimen was also not associated with a difference in severe POM (odds ratio 0.42, 95% confidence interval 0.04-4.70, P = 0.48) in multivariate analysis. There was no significant association between neoadjuvant regimen and any secondary outcome. CONCLUSION: In rectal cancer patients treated with SC-TNT and proctectomy, we found no significant association with POM compared to patients undergoing CRT. SC-TNT does not significantly increase the risk of POM compared to CRT.
引用
- Bauer PS, Chapman WC, Atallah C, et al. Perioperative Complications After Proctectomy for Rectal Cancer: Does Neoadjuvant Regimen Matter? Ann Surg. 2022. PMID: 32209914. doi:10.1097/SLA.0000000000003885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。